



## The subscription price for exercise of warrants of series TO1 in Emplicure has been determined to SEK 2.09 per share

During the second quarter of 2021, Emplicure AB (publ) (“Emplicure” or “the Company”) issued 9,600,000 warrants of series TO1. Each warrant entitles the holder to subscribe for one (1) new share in the Company. According to the board of directors’ resolution, which was resolved pursuant to the authorization by the annual general meeting held on 13 April 2021, the subscription price for the warrants of series TO1 shall be set at 70 percent of the volume-weighted average price of the Company’s share on Nasdaq First North Growth Market during the measurement period from and including 12 April 2022 up to and including 27 April 2022, provided however that the subscription price may not be determined to an amount less than the quota value for the Company’s shares and not be determined to an amount exceeding SEK 6.23 per share. The volume-weighted average price of the Company’s share during the measurement period amounted to approximately SEK 2.98 and the subscription price has thus been set at SEK 2.09. Subscription of shares with through the exercise of warrants of series TO1 shall be made during the period from and including 29 April 2022 up to and including 13 May 2022.

Complete terms and conditions for the warrants are available at the Company’s website, [www.emplicure.com](http://www.emplicure.com).

### Summarized terms for warrants of series TO1:

Exercise period: From 29 April 2022 up to and including 13 May 2022.

Subscription price: SEK 2.09 per share.

Volume: 9,600,000 warrants of series TO1. If all the warrants of series TO1 are exercised, the number of shares in the Company will increase with 9,600,00 shares, and the Company will receive approximately SEK 20.1 million before issuing costs.

Last day for trading with warrants of series TO1: 11 May 2022.

### Advisors

Mangold Fondkommission AB is the financial advisor and issuing agent and Advokatfirman Lindahl KB is the legal advisor to Emplicure in connection with the exercise of the warrants.

### For further information, please contact:

Torbjörn W. Larsson

CEO, Emplicure

Telephone: +46 707 476 599

E-mail: [torbjorn.walkerlarsson@emplicure.com](mailto:torbjorn.walkerlarsson@emplicure.com)

Erik Magnusson

CFO & Investor Relations, Emplicure

Telephone: +46 708 565 245

E-mail: [erik.magnusson@emplicure.com](mailto:erik.magnusson@emplicure.com)

### About Emplicure

Emplicure is a pharmaceutical company developing new and innovative drugs by combining existing and approved active substances, and advanced materials science within ceramic biomaterials. The product portfolio is focused on chronic pain, and with abuse deterrent formulations. The wholly owned subsidiary, Amplicon AB develops consumer products, with white oral nicotine as the first product.

Read more at [www.emplicure.com](http://www.emplicure.com)